LeBlanc E S, Janowsky J, Chan B K, Nelson H D
Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Mail Code HRC3, Portland, OR 97201-3098, USA.
JAMA. 2001 Mar 21;285(11):1489-99. doi: 10.1001/jama.285.11.1489.
Some observational data suggest that hormone replacement therapy (HRT) may reduce the risk of cognitive decline and dementia but results have been conflicting.
To review and evaluate studies of HRT for preventing cognitive decline and dementia in healthy postmenopausal women.
Studies with English-language abstracts identified in MEDLINE (1966-August 2000), HealthSTAR (1975-August 2000, PsychINFO (1984-August 2000); Cochrane Library databases; and articles listed in reference lists of key articles.
Randomized controlled trials and cohort studies were reviewed for the effects of HRT on cognitive decline; cohort and case-control studies were reviewed for dementia risk. No randomized controlled trials regarding dementia risk were identified.
Twenty-nine studies met inclusion criteria and were rated. Two reviewers rated study quality independently and 100% agreement was reached on Jadad scores and 80% agreement was reached on US Preventive Services Task Force quality scores. A final score was reached through consensus if reviewers disagreed.
Studies of cognition were not combined quantitatively because of heterogeneous study design. Women symptomatic from menopause had improvements in verbal memory, vigilance, reasoning, and motor speed, but no enhancement of other cognitive functions. Generally, no benefits were observed in asymptomatic women. A meta-analysis of observational studies suggested that HRT was associated with a decreased risk of dementia (summary odds ratio, 0.66; 95% confidence interval, 0.53-0.82). However, possible biases and lack of control for potential confounders limit interpretation of these studies. Studies did not contain enough information to assess adequately the effects of progestin use, various estrogen preparations or doses, or duration of therapy.
In women with menopausal symptoms, HRT may have specific cognitive effects, and future studies should target these effects. The meta-analysis found a decreased risk of dementia in HRT users but most studies had important methodological limitations.
一些观察性数据表明,激素替代疗法(HRT)可能会降低认知能力下降和患痴呆症的风险,但研究结果一直存在矛盾。
回顾和评估激素替代疗法预防健康绝经后女性认知能力下降和痴呆症的研究。
在MEDLINE(1966年至2000年8月)、HealthSTAR(1975年至2000年8月)、PsychINFO(1984年至2000年8月)中检索到的带有英文摘要的研究;Cochrane图书馆数据库;以及关键文章参考文献列表中列出的文章。
对激素替代疗法对认知能力下降影响的随机对照试验和队列研究进行了回顾;对痴呆症风险的队列研究和病例对照研究进行了回顾。未发现关于痴呆症风险的随机对照试验。
29项研究符合纳入标准并进行了评分。两名评审员独立对研究质量进行评分,在Jadad评分上达成了100%的一致,在美国预防服务工作组质量评分上达成了80%的一致。如果评审员存在分歧,则通过协商达成最终评分。
由于研究设计的异质性,未对认知研究进行定量合并。有更年期症状的女性在言语记忆、警觉性、推理和运动速度方面有所改善,但其他认知功能没有增强。一般来说,无症状女性未观察到益处。一项观察性研究的荟萃分析表明,激素替代疗法与痴呆症风险降低相关(汇总比值比,0.66;95%置信区间,0.53 - 0.82)。然而,可能存在的偏倚和对潜在混杂因素缺乏控制限制了这些研究的解释。研究没有包含足够的信息来充分评估孕激素的使用、各种雌激素制剂或剂量或治疗持续时间的影响。
对于有更年期症状的女性,激素替代疗法可能有特定的认知作用,未来的研究应针对这些作用。荟萃分析发现激素替代疗法使用者患痴呆症的风险降低,但大多数研究存在重要的方法学局限性。